Urocortins in heart failure

Biochemical Pharmacology

Volumn 80, Issue 3, 2010, Pages 289-296

  Venkatasubramanian, Sowmya ^a   Newby, David E ^a   Lang, Ninian N ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cardiovascular; Corticotrophin releasing hormone; Heart failure; Urocortins

Indexed keywords

ADENYLATE CYCLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARDIOTROPHIN 1; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; UROCORTIN; UROCORTIN I; UROCORTIN II; UROCORTIN III;

ANTIDIURESIS; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR EFFECT; COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HORMONE ACTION; HUMAN; MONOTHERAPY; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; VASODILATATION;

ANIMALS; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; SIGNAL TRANSDUCTION; UROCORTINS; VASODILATION;

EID: 77953360611     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.03.032     Document Type: Note

References (64)

1. American Heart Association Heart disease and stroke facts. 2006 update 2006, AHA, Dallas, TX.
2. Fekete E.M., Zorrilla E.P. Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front. Neuroendocrinol. 2007, 28:1-27.
3. Boonprasert P., Lailerd N., Chattipakorn N. Urocortins in heart failure and ischemic heart disease. Int J Cardiol 2008, 127:307-312.
4. Vaughan J., Donaldson C., Bittencourt J., Perrin M., Lewis K., Sutton S., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995, 378:287-291.
5. Skelton K.H., Owens M.J., Nemeroff C.B. The neurobiology of urocortin. Regul Pept 2000, 93:85-92.
6. Davidson S.M., Rybka A.E., Townsend P.A. The powerful cardioprotective effects of urocortin and the corticotropin releasing hormone (CRH) family. Biochem Pharmacol 2009, 77:141-150.
7. Davidson S.M., Yellon D.M. Urocortin: a protective peptide that targets both the myocardium and vasculature. Pharmacol Rep 2009, 61:172-182.
8. Hillhouse E.W., Grammatopoulos D.K. The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 2006, 27:260-286.
9. Vamvakopoulos N.C., Sioutopoulou T.O. Human corticotropin-releasing hormone receptor gene (CRHR) is located on the long arm of chromosome 17 (17q12-qter). Chromosome Res 1994, 2:471-473.
10. Meyer A.H., Ullmer C., Schmuck K., Morel C., Wishart W., Lübbert H., et al. Localization of the human CRF2 receptor to 7p21-p15 by radiation hybrid mapping and FISH analysis. Genomics 1997, 40:189-190.
11. Hsu S.Y., Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001, 7:605-611.
12. Oki Y., Sasano H. Localization and physiological roles of urocortin. Peptides 2004, 25:1745-1749.
13. Takahashi K., Totsune K., Murakami O., Saruta M., Nakabayashi M., Suzuki T., et al. Expression of urocortin III/stresscopin in human heart and kidney. J Clin Endocrinol Metab 2004, 89:1897-1903.
14. Kimura Y., Takahashi K., Totsune K., Muramatsu Y., Kaneko C., Darnel A.D., et al. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 2002, 87:340-346.
15. Wiley K.E., Davenport A.P. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol 2004, 143:508-514.
16. Grace C.R.R., Perrin M.H., Cantle J.P., Vale W.W., Rivier J.E., Riek R. Common and divergent structural features of a series of corticotropin releasing factor-related peptides. J Am Chem Soc 2007, 129:16102-16114.
17. Davis M.E., Pemberton C.J., Yandle T.G., Lainchbury J.G., Rademaker M.T., Nicholls M.G., et al. Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab 2004, 89:1402-1409.
18. Davis M., Pemberton C., Yandle T., Lainchbury J., Rademaker M., Nicholls M., et al. Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci 2005, 109:381-388.
19. Davis M.E., Pemberton C.J., Yandle T.G., Fisher S.F., Lainchbury J.G., Frampton C.M., et al. Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. J Am Coll Cardiol 2007, 49:461-471.
20. Rademaker M., Cameron V., Charles C., Richards A. Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 2006, 27:2088.
21. Behan D.P., Linton E.A., Lowry P.J. Isolation of the human plasma corticotrophin-releasing factor-binding protein. J Endocrinol 1989, 122:23-31.
22. Potter E., Behan D.P., Linton E.A., Lowry P.J., Sawchenko P.E., Vale W.W. The central distribution of a corticotropin-releasing factor (CRF)-binding protein predicts multiple sites and modes of interaction with CRF. Proc Natl Acad Sci USA 1992, 89:4192-4196.
23. Lovejoy D.A., Aubry J.M., Turnbull A., Sutton S., Potter E., Yehling J., et al. Ectopic expression of the CRF-binding protein: minor impact on HPA axis regulation but induction of sexually dimorphic weight gain. J Neuroendocrinol 1998, 10:483-491.
24. Petraglia F., Potter E., Cameron V.A., Sutton S., Behan D.P., Woods R.J., et al. Corticotropin-releasing factor-binding protein is produced by human placenta and intrauterine tissues. J Clin Endocrinol Metab 1993, 77:919-924.
25. Rademaker M.T., Charles C.J., Espiner E.A., Fisher S., Frampton C.M., Kirkpatrick C.M.J., et al. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol 2002, 40:1495-1505.
26. Kageyama K., Furukawa K.-I., Miki I., Terui K., Motomura S., Suda T. Vasodilative effects of urocortin II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta. J Cardiovasc Pharmacol 2003, 42:561-565.
27. Kageyama K., Gaudriault G.E., Suda T., Vale W.W. Regulation of corticotropin-releasing factor receptor type 2beta mRNA via cyclic AMP pathway in A7r5 aortic smooth muscle cells. Cell Signal 2003, 15:17-25.
28. Brar B.K., Jonassen A.K., Stephanou A., Santilli G., Railson J., Knight R.A., et al. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 2000, 275:8508-8514.
29. Clifton V.L., Read M.A., Leitch I.M., Giles W.B., Boura A.L., Robinson P.J., et al. Corticotropin-releasing hormone-induced vasodilatation in the human fetal-placental circulation: involvement of the nitric oxide-cyclic guanosine 3',5'-monophosphate-mediated pathway. J Clin Endocrinol Metab 1995, 80:2888-2893.
30. Chen Z.-W., Huang Y., Yang Q., Li X., Wei W., He G.-W. Urocortin-induced relaxation in the human internal mammary artery. Cardiovasc Res 2005, 65:913-920.
31. Huang Y., Chan F., Lau C., Tsang S., He G., Chen Z., et al. Urocortin-induced endothelium-dependent relaxation of rat coronary artery: role of nitric oxide and K+ channels. B J Pharmacol 2002, 135:1467.
32. Tsatsanis C., Androulidaki A., Dermitzaki E., Charalampopoulos I., Spiess J., Gravanis A., et al. Urocortin 1 and Urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett 2005, 579:4259-4264.
33. Coste S.C., Kesterson R.A., Heldwein K.A., Stevens S.L., Heard A.D., Hollis J.H., et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 2000, 24:403-409.
34. Briscoe R.J., Cabrera C.L., Baird T.J., Rice K.C., Woods J.H. Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats. Brain Res 2000, 881:204-207.
35. Coste S.C., Quintos R.F., Stenzel-Poore M.P. Corticotropin-releasing hormone-related peptides and receptors: emergent regulators of cardiovascular adaptations to stress. Trends Cardiovasc Med 2002, 12:176-182.
36. Chen C.-Y., Doong M.-L., Rivier J.E., Taché Y. Intravenous urocortin II decreases blood pressure through CRF(2) receptor in rats. Regul Pept 2003, 113:125-130.
37. Dieterle T., Meili-Butz S., Bühler K., Morandi C., John D., Buser P.T., et al. Immediate and sustained blood pressure lowering by urocortin 2: a novel approach to antihypertensive therapy?. Hypertension 2009, 53:739-744.
38. Smani T., Domínguez-Rodríguez A., Hmadcha A., Calderón-Sánchez E., Horrillo-Ledesma A., Ordóñez A. Role of Ca2+-independent phospholipase A2 and store-operated pathway in urocortin-induced vasodilatation of rat coronary artery. Circ Res 2007, 101:1194-1203.
39. Yang L.-Z., Kockskämper J., Heinzel F.R., Hauber M., Walther S., Spiess J., et al. Urocortin II enhances contractility in rabbit ventricular myocytes via CRF(2) receptor-mediated stimulation of protein kinase A. Cardiovasc Res 2006, 69:402-411.
40. Parkes D.G., Weisinger R.S., May C.N. Cardiovascular actions of CRH and urocortin: an update. Peptides 2001, 22:821-827.
41. Brar B.K., Stephanou A., Okosi A., Lawrence K.M., Knight R.A., Marber M.S., et al. CRH-like peptides protect cardiac myocytes from lethal ischaemic injury. Mol Cell Endocrinol 1999, 158:55-63.
42. Talwar S., Squire I.B., Downie P.F., O'Brien R.J., Davies J.E., Ng L.L. Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci 2000, 99:83-88.
43. Brar B.K., Railson J., Stephanou A., Knight R.A., Latchman D.S. Urocortin increases the expression of heat shock protein 90 in rat cardiac myocytes in a MEK1/2-dependent manner. J Endocrinol 2002, 172:283-293.
44. Lawrence K.M., Scarabelli T.M., Turtle L., Chanalaris A., Townsend P.A., Carroll C.J., et al. Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium-insensitive phospholipase A2 gene expression. FASEB J 2003, 17:2313-2315.
45. Brar B., Jonassen A., Egorina E., Chen A., Negro A., Perrin M., et al. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 2004, 145:24-35.
46. Yang C., Xu Y., Li S. Urocortin: a beneficial or detrimental agent to endothelium?. Biochem Biophys Res Commun 2008, 371:345-349.
47. Ganz P., Vita J.A. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 2003, 108:2049-2053.
48. Behrendt D., Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002, 90:40L-48L.
49. Nishikimi T., Miyata A., Horio T., Yoshihara F., Nagaya N., Takishita S., et al. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 2000, 279:H3031-H3039.
50. Ikeda K., Tojo K., Sato S., Ebisawa T., Tokudome G., Hosoya T., et al. Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes. Biochem Biophys Res Commun 1998, 250:298-304.
51. Ng L.L., Loke I.W., O'Brien R.J., Squire I.B., Davies J.E. Plasma urocortin in human systolic heart failure. Clin Sci 2004, 106:383-388.
52. Charles C.J., Rademaker M.T., Richards A.M., Yandle T.G. Plasma urocortin 1 in sheep: regional sampling and effects of experimental heart failure. Peptides 2006, 27:1801-1805.
53. Rademaker M.T., Charles C.J., Richards A.M. Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure. Am J Physiol Heart Circ Physiol 2007, 293:H1536-H1544.
54. Sanz E., Monge L., Fernández N., Martínez M.A., Martínez-León J.B., Diéguez G., et al. Relaxation by urocortin of human saphenous veins. Br J Pharmacol 2002, 136:90-94.
55. Bale T.L., Hoshijima M., Gu Y., Dalton N., Anderson K.R., Lee K.-F., et al. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 2004, 101:3697-3702.
56. Rademaker M.T., Charles C.J., Nicholls M.G., Richards A.M. Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure. Clin Sci 2008, 114:635-642.
57. Rademaker M., Charles C., Nicholls M Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function. Circ Heart Fail 2009, 532-540.
58. Rademaker M., Cameron V., Charles C., Richards A. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 2005, 112:3624.
59. Wright S.P., Doughty R.N., Frampton C.M., Gamble G.D., Yandle T.G., Richards A.M. Plasma urocortin 1 in human heart failure. Circ Heart Fail 2009, 2:465-471.
60. Davis M.E., Pemberton C.J., Yandle T.G., Fisher S.F., Lainchbury J.G., Frampton C.M., et al. Urocortin 2 infusion in human heart failure. Eur Heart J 2007, 28:2589-2597.
61. Rademaker M.T., Charles C.J., Espiner E.A., Frampton C.M., Lainchbury J.G., Richards A.M. Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure. Eur Heart J 2005, 26:2046-2054.
62. Davis M., Pemberton C., Yandle T., Fisher S., Lainchbury J., Frampton C., et al. Urocortin 2 infusion in human heart failure. Eur Heart J 2007, 28:2589.
63. Rademaker M.T., Charles C.J., Espiner E.A., Frampton C.M., Lainchbury J.G., Richards A.M. Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 2005, 26:2055-2062.
64. Ikeda K., Tojo K., Tokudome G., Hosoya T., Tajima N., Oki Y., et al. Urocortin is an endogenous cardio-protective factor against negative effects of cytokines in the heart. Abstract of paper presented at the Endocrine Society's 83rd annual meeting 2001.